文献速递心脑血管急症重症综合管理与镇静镇痛

糖化血红蛋白与接受治疗性低温的心脏骤停存活者血糖控制及6个月神经功能结局相关

Glycated Hemoglobin is Associated with Glycemic Control and 6-Month Neurologic Outcome in Cardiac Arrest Survivors Undergoing Therapeutic Hypothermia.
PubMed 文献 · Neurocrit Care · 2020-01-01
一句话结论在心脏骤停后接受治疗性低温的昏迷存活者中,较高的糖化血红蛋白(HbA1c)与6个月不良神经功能结局独立相关,但与治疗性低温期间的各项血糖指标各自独立预测结局无关。

这项回顾性单中心研究纳入2011年9月至2017年12月接受治疗性低温(TH)的成人昏迷心脏骤停存活者384例,以HbA1c 6.4%为界分为正常与高HbA1c组。高HbA1c组81例(21.1%),247例(64.3%)6个月神经功能结局不良。不良结局组高HbA1c比例更高(27.5% vs 9.5%,p < 0.001),HbA1c水平更高(5.8%[5.4-6.8%]vs 5.6%[5.3-6.0%],p = 0.007);HbA1c水平独立关联更差的神经功能结局(OR 1.414;95%CI 1.051-1.903)。高HbA1c组ROSC后血糖、维持期及复温期血糖AUC更高,TH期间高血糖发生率更高,而正常HbA1c组血糖正常发生率更高;但校正后无论HbA1c水平如何,没有任何血糖参数是神经功能结局的独立预测因子。

要点

  • 384例接受治疗性低温的成人昏迷心脏骤停存活者中,247例(64.3%)6个月神经功能结局不良(CPC 3-5)。
  • 不良结局组高HbA1c(>6.4%)比例27.5% vs 9.5%(p < 0.001),HbA1c水平5.8% vs 5.6%(p = 0.007)。
  • HbA1c水平独立关联更差神经功能结局:OR 1.414(95%CI 1.051-1.903)。
  • 高HbA1c组ROSC后血糖、维持期及复温期血糖AUC更高,TH期间高血糖发生率更高;正常HbA1c组血糖正常发生率更高。
  • 校正后无论HbA1c水平如何,没有任何血糖参数是神经功能结局的独立预测因子;NSE预后效能好(AUC 0.892,界值26.3 ng/mL)。

适用人群与场景

  • 2011年9月至2017年12月接受治疗性低温的成人昏迷心脏骤停存活者,共384例。
  • 高HbA1c定义为HbA1c > 6.4%,共81例(21.1%);HbA1c在ROSC后测定。

诊断标准与关键阈值

  • 高HbA1c:HbA1c > 6.4%;正常HbA1c:HbA1c ≤ 6.4%。
  • 低血糖:血糖 < 70 mg/dL;高血糖:血糖 > 180 mg/dL。
  • 血糖目标范围80-200 mg/dL,至少每4小时测一次血糖并按书面方案处理。
  • 主要结局为不良神经功能结局:心脏骤停后6个月格拉斯哥-匹兹堡脑功能表现分类(CPC)3-5级。

处置流程与药物剂量

  • 按书面方案维持血糖80-200 mg/dL,至少每4小时测一次血糖。
  • 计算诱导期与复温期平均血糖,以及维持期每6小时血糖曲线下面积(AUC)。
  • 记录心脏骤停后48小时神经元特异性烯醇化酶(NSE)。

研究设计与关键结果

  • 回顾性单中心研究,纳入384例接受治疗性低温的成人昏迷心脏骤停存活者;247例(64.3%)6个月神经功能结局不良。
  • 不良结局组高HbA1c比例27.5% vs 9.5%(p < 0.001);HbA1c水平5.8%(5.4-6.8%)vs 5.6%(5.3-6.0%)(p = 0.007)。
  • HbA1c水平独立关联更差神经功能结局:OR 1.414(95%CI 1.051-1.903)。
  • 高HbA1c组ROSC后血糖、维持期血糖AUC、复温期血糖均高于正常HbA1c组;高HbA1c组TH期间高血糖发生率更高,正常HbA1c组血糖正常发生率更高。
  • 校正后无论HbA1c水平如何,没有任何血糖参数是神经功能结局的独立预测因子。
  • NSE预后效能好(AUC 0.892,界值26.3 ng/mL);两HbA1c组间NSE水平无差异,但高HbA1c组NSE超过界值的比例更高。

证据类型、等级与局限

  • 研究类型:回顾性单中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对接受治疗性低温的心脏骤停存活者,入院时可检测HbA1c以识别慢性高血糖状态,该指标独立关联6个月不良神经功能结局。
  • 作者结论:较高的HbA1c独立关联不良神经功能结局;正常与高HbA1c组在治疗性低温期间的血糖状态不同。
  • 校正后各项血糖参数均非神经功能结局的独立预测因子,原文未据此给出改变血糖管理目标的推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Glucose control status after cardiac arrest depending on chronic glycemic status and the association between chronic glycemic status and outcome in cardiac arrest survivors are not well known. We investigated the association between glycated hemoglobin (HbA1c) and 6-month neurologic outcome in cardiac arrest survivors undergoing therapeutic hypothermia (TH) and whether mean glucose, area under curve (AUC) of glucose during TH, and neuron-specific enolase (NSE) are different between normal and high HbA1c groups.

METHODS: This retrospective single-center study included adult comatose cardiac arrest survivors who underwent TH from September 2011 to December 2017. HbA1c and glucose were measured after return of spontaneous circulation (ROSC), and normal or high HbA1c was defined using cutoff value of 6.4% of HbA1c. Blood glucose was measured at least every 4 h and treated with a written protocol to maintain the range of 80-200 mg/dL. Hypoglycemia and hyperglycemia were defined with glucose < 70 or > 180 mg/dL. Mean glucose during induction and rewarming phase and AUC of glucose during every 6 h of maintenance were calculated, and NSE at 48 h after cardiac arrest was recorded. The primary outcome was unfavorable neurologic outcome, defined as Glasgow Pittsburgh Cerebral Performance Category scale 3-5 at 6 months after cardiac arrest.

RESULTS: Of 384 included patients, 81 (21.1%) had high HbA1c and 247 (64.3%) had an unfavorable neurologic outcome. Patients with high HbA1c were more common in the unfavorable group than in favorable group (27.5% vs 9.5%, p < 0.001), and the unfavorable group had significantly higher HbA1c level (5.8% [5.4-6.8%] vs 5.6% [5.3-6.0%], p = 0.007). HbA1c level was independently associated with worse neurologic outcome (odds ratio 1.414; 95% confidence interval 1.051-1.903). High HbA1c group had higher glucose after ROSC, glucose AUC during maintenance, and rewarming phase than normal HbA1c group. High HbA1c group had significantly higher incidence of hyperglycemia throughout the TH, while normal HbA1c group had significantly higher incidence of normoglycemia. However, no glucose parameter remained as an independent predictor of neurologic outcome after adjustment, irrespective of HbA1c level. NSE showed good prognostic performance (area under curve 0.892; cutoff value 26.3 ng/mL). Although NSE level was not different between HbA1c groups, high HbA1c group had higher proportion of patient having NSE over cutoff.

CONCLUSIONS: Higher HbA1c was independently associated with unfavorable neurologic outcome. Glycemic status during TH was different between normal and high HbA1c groups.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Lee BK, Lee DH, Jeung KW, et al. Glycated Hemoglobin is Associated with Glycemic Control and 6-Month Neurologic Outcome in Cardiac Arrest Survivors Undergoing Therapeutic Hypothermia. Neurocrit Care. 2020. PMID: 31187435. doi:10.1007/s12028-019-00758-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。